Influence of vedolizumab on extraintestinal manifestations in inflammatory bowel disease: a nationwide multicenter study of the GETECCU ENEIDA Registry


Por: Pérez-Galindo, P, Gisbert, JP, Carrillo-Palau, M, Bertoletti, F, González-Vivó, M, Pajares, R, Merino, O, Ferrer, JA, Castaño, A, Chaparro, M, Calvo, M, Acosta, MBD, Lorente, RH, Algaba, A, Madero-Velázquez, L, Vela, M, de la Maza, S, Llaó, J, Vega, P, Utrilla, A, Almela, P, Domènech, E and Carpio, D

Publicada: 1 mar 2026
Resumen:
Background and Aims Evidence regarding the influence of vedolizumab (VDZ) on extraintestinal manifestations (EIMs) of inflammatory bowel disease (IBD) is limited. Our aim was to analyze the effectiveness of VDZ in preexisting EIMs and the occurrence of de novo EIMs during VDZ therapy for IBD.Methods This observational, multicenter, retrospective cohort study included patients from the Spanish ENEIDA registry. All EIMs were assessed at baseline, and clinical response and worsening of IBD and EIMs were evaluated at 3 and 12 months after VDZ initiation, according to the physician's assessment.Results We retrospectively identified 551 patients with IBD treated with VDZ. At baseline, 133 patients (24.1%) had preexisting EIMs, with 77 having active EIMs. At 3 months, 29.9% of these patients showed clinical improvement, 16.9% experienced worsening, and 53.2% remained unchanged. Clinical response of IBD at 3 months was the only factor associated with EIM improvement (OR 3.72; 95% CI 1.08-12.83). Among 56 patients with inactive EIMs at baseline, 13.5% experienced worsening after 12 months. During follow-up, 25 patients (4.5%) developed 27 de novo EIMs. The presence of 2 preexisting EIMs was the only factor associated with de novo EIM onset (OR 16.2; 95% CI 4.3-60.9). Worsening of preexisting EIMs or de novo EIMs led to VDZ discontinuation in 15 patients (5.8% of all patients who discontinued VDZ and 2.7% of the entire cohort).Conclusions VDZ achieved clinical response of active EIMs in nearly one-third of patients after 3 months. Although infrequent, VDZ may exacerbate inactive EIMs and induce de novo EIMs during therapy, potentially leading to treatment discontinuation.

Filiaciones:
Pérez-Galindo, P:
 Complejo Hosp Univ Pontevedra, Inst Invest Sanitaria Galicia Sur IISGS, Pontevedra, Spain

Gisbert, JP:
 Univ Autonoma Madrid UAM, Inst Invest Sanitaria Princesa IIS IP, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Hosp Univ La Princesa, Madrid, Spain

Carrillo-Palau, M:
 Hosp Univ Canarias, Tenerife, Spain

Bertoletti, F:
 Hosp Santa Creu & Sant Pau, Barcelona, Spain

González-Vivó, M:
 Hosp del Mar, Barcelona, Spain

Pajares, R:
 Hosp Univ Infanta Sofia, Madrid, Spain

Merino, O:
 Hosp Univ Cruces, Baracaldo, Spain

Ferrer, JA:
 Hosp Univ Fdn Alcorcon, Madrid, Spain

Castaño, A:
 Hosp Univ Cent Asturias, Oviedo, Spain

Chaparro, M:
 Univ Autonoma Madrid UAM, Inst Invest Sanitaria Princesa IIS IP, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Hosp Univ La Princesa, Madrid, Spain

Calvo, M:
 Hosp Univ Puerta Hierro, Madrid, Spain

Acosta, MBD:
 Hosp Clin Univ Santiago de Compostela, Santiago De Compostela, Spain

Lorente, RH:
 Hosp Gen Univ Ciudad Real, Ciudad Real, Spain

Algaba, A:
 Hosp Univ Fuenlabrada, Madrid, Spain

Madero-Velázquez, L:
 Hosp Gen Univ Dr Balmis, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Alicante, Spain

Vela, M:
 Hosp Univ Nuestra Senora Candelaria, Santa Cruz de Tenerife, Spain

de la Maza, S:
 Hosp Univ Basurto, Bilbao, Spain

Llaó, J:
 Xarxa Assistencial Univ, Althaia, Manresa, Spain

Vega, P:
 Complexo Hosp Univ Ourense, Orense, Spain

Utrilla, A:
 Hosp Gen San Jorge, Huesca, Spain

Almela, P:
 Hosp Gen Univ Castellon, Castellon de La Plana, Spain

:
 Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain

Carpio, D:
 Complejo Hosp Univ Pontevedra, Inst Invest Sanitaria Galicia Sur IISGS, Pontevedra, Spain
ISSN: 18739946





JOURNAL OF CROHNS & COLITIS
Editorial
Oxford University Press, GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 20 Número: 3
Páginas:
WOS Id: 001723868100001
ID de PubMed: 41886507

MÉTRICAS